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Introduction
Gastro-oesophageal reﬂux disease (GERD) is one of
the most common gastrointestinal diseases that pri-
mary care physicians (PCPs) encounter in daily prac-
tice, with up to 20% of the population of developed
countries being affected by at least weekly reﬂux
symptoms (1,2). This chronic and potentially serious
condition results from continued exposure of the
oesophageal mucosa to reﬂuxed gastric contents,
which carries a risk of erosive oesophageal tissue
damage and subsequent (albeit relatively rare) com-
plications, such as stricture and Barrett’s oesophagus
(3). However, many patients with typical GERD
symptoms do not have endoscopically visible erosive
disease (3–5), indicating that endoscopy (while
highly speciﬁc for diagnosis of GERD) is of limited
value in guiding disease management (6,7). Indeed,
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SUMMARY
Aim: To review, from a primary care physician (PCP) perspective, the use of
patient-reported outcome (PRO) instruments for assessment of gastro-oesophageal
reﬂux disease (GERD) symptoms, their impact on health-related quality of life
(HRQL) and the effectiveness of therapy. Results: While generic and disease-spe-
ciﬁc PRO instruments have been used in the assessment of GERD, the latter can
be considered to be more appropriate as they focus only on problems relevant to
the disease in question (and therefore tend to be more responsive to change).
Such instruments include the Quality of Life in Reﬂux and Dyspepsia (QOLRAD)
questionnaire and the Gastrointestinal Symptom Rating Scale and the Reﬂux Dis-
ease Questionnaire (RDQ). Their use indicates that GERD symptoms are trouble-
some and signiﬁcantly reduce patients’ HRQL, and that effective treatment of
GERD improves HRQL. The GERD Impact Scale (GIS) questionnaire, primarily devel-
oped for use within primary care, can also help to determine the impact of symp-
toms on patients’ everyday lives and, in turn, the beneﬁt of appropriately targeted
therapy. Notably, these PRO instruments were developed from focus groups of
GERD patients, and only aspects rated of highest importance are used in the ﬁnal
instruments. Consequently, PCPs can feel conﬁdent that these questionnaires
encompass the most relevant points that they are likely to ask in terms of how
symptoms affect patients’ everyday lives. Conclusions: Primary care physicians are
encouraged to make wider use of PRO instruments within routine practice to
improve communication with their GERD patients that, in turn, could lead to
improved clinical outcomes and greater patient satisfaction.
Review Criteria
• We conducted a review of validated patient-
reported outcome (PRO) instruments used in
gastro-oesophageal reﬂux disease (GERD), based
on the authors’ expertise in the ﬁeld and a
supplementary MEDLINE search with the terms
‘health-related quality of life’, ‘quality of life
questionnaire’, ‘patient-reported outcomes’,
‘patient satisfaction’ and ‘gastro-oesophageal
reﬂux disease’.
• We reviewed papers reporting health-related
quality of life (HRQL) data in patients with GERD,
including the effect of GERD on HRQL, treatment
efﬁcacy and HRQL, patient satisfaction and
physician-patient agreement, to help primary care
physicians to incorporate PRO instruments into
their day-to-day management of patients with
GERD.
Message for the Clinic
• An evidence-based review shows that PRO
instruments can accurately assess the nature of
GERD symptoms, their impact on HRQL and the
efﬁcacy of treatment.
• Primary care physicians are encouraged to make
wider use of PRO instruments as part of their
management of patients with GERD, given that
such questionnaires can facilitate patient
communication and help physicians understand
and satisfy the therapeutic needs of their
patients.
• Among validated PRO instruments, the GERD
Impact Scale represents a practical tool that is
easy for primary care physicians to incorporate
into their everyday practice.
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approach to the diagnosis of GERD in patients with-
out ‘alarm’ features (i.e. those suggestive of cancer,
such as persistent vomiting, bleeding, anaemia, dys-
phagia, weight loss and abdominal mass) (6–9).
Patients with GERD may present with a broad
range of troublesome symptoms that can extend
beyond the cardinal symptoms of heartburn and
regurgitation (10). Symptoms can overlap with other
gastrointestinal diseases (such as dyspepsia) (11), and
may even include chest pain or extra-oesophageal
manifestations, such as chronic cough and asthma
(10,12). GERD symptoms are a major burden for
many patients, in terms of disrupted physical, social
and emotional well-being (13), leading an interna-
tional expert panel to propose that GERD be deﬁned
as reﬂux symptoms sufﬁcient to impair patients’ lives
(8). Indeed, a recent global consensus on GERD has
agreed upon a new deﬁnition that includes symp-
toms (and/or complications) that can be attributed
to GERD and that are troublesome. This adds a
patient-deﬁned qualiﬁer indicating that the severity
of symptoms is sufﬁcient to impair their quality of
life and/or limit their function (10). In the present
article, we review how patient-reported outcome
(PRO) instruments can be used not only to assess
this burden but also to support optimal management
of GERD by PCPs.
Patient-reported outcome instruments
Two basic types of PRO instrument can be used to
measure health-related quality of life (HRQL): ‘gen-
eric’ and ‘disease-speciﬁc’. ‘Generic’ instruments are
designed to evaluate functional status and well-being
in general populations, whereas ‘disease-speciﬁc’
instruments focus only on problems relevant to the
disease in question (14). Examples of the generic and
disease-speciﬁc PRO instruments that have been used
to assess GERD symptoms and their effect on HRQL
are summarised in Table 1. Patients generally ﬁnd
these PRO instruments quick and easy to complete,
which facilitates their use both in the research setting
and for everyday primary care practice. Notably,
however, disease-speciﬁc instruments are probably
more appropriate for use in the day-to-day manage-
ment of GERD patients, because they are not only
speciﬁc to GERD (or gastrointestinal symptoms in
general) but also tend to be more responsive to
change. One example of a disease-speciﬁc PRO
instrument is the fully validated Quality of Life in
Reﬂux and Dyspepsia (QOLRAD) questionnaire
(18), which was developed for patients suffering
from upper gastrointestinal symptoms including
heartburn and dyspepsia. QOLRAD monitors HRQL
across a full range of clinically relevant aspects, such
as emotional distress, sleep disturbance, and food
and drink problems in the past week. Other disease-
speciﬁc PRO instruments include the Gastrointestinal
Symptom Rating Scale (GSRS) (19), which evaluates
how patients perceive the severity of their gastroin-
testinal symptoms over the past week. The GSRS was
originally developed in patients with irritable bowel
syndrome and peptic ulcer disease, but has since
been speciﬁcally evaluated for use in patients with
GERD (22). The Reﬂux Disease Questionnaire
(RDQ) (20), another self-administered questionnaire,
was designed to assess the frequency and severity of
heartburn, acid regurgitation and dyspeptic com-
plaints (pain or burning in the upper stomach) over
the past week. Such questionnaires have generally
proved easy-to-use, although some take longer to
complete than others and this could be a problem
for some patients under certain circumstances. More
recently, a one-page, patient-completed and short
questionnaire known as the GERD Impact Scale
(GIS) (21) (Figure 1) has been developed which is
intended to quickly determine the burden and
impact of GERD symptoms over the last week. Com-
prised of nine self-explanatory questions, for which
patients tick one of four options to describe how
often they are affected (‘daily’, ‘often’, ‘sometimes’
and ‘never’), the GIS can be completed by the
patient without input from his/her physician, e.g. at
the start of a consultation. Questions about symptom
burden ask the patient to estimate the frequency of
symptoms and the use of supplementary (over-the-
counter) medication to control symptoms, while the
impact of symptoms is assessed by inquiring about
their effect on sleep and the ability to eat and drink.
The adverse impact of GERD symptoms on the latter
aspects of daily life, as well as work performance and
concomitant high usage of over-the-counter medica-
tion, is not always recognised by clinicians and
together indicate that GERD symptoms are promi-
nent and far from being well-controlled. Hence the
intent of using the GIS is not only to raise awareness
of GERD symptoms and their impact but also to
provide a simple tool to monitor how patients
respond to treatment for their GERD symptoms. The
GSRS, RDQ and the GIS therefore allow for the
assessment of subjective HRQL in relation to physi-
cian-perceived symptom severity and frequency. This
is particularly relevant considering that physicians
often underestimate the severity and impact of their
patients’ GERD symptoms (8). Notably, PRO instru-
ments such as, QOLRAD, RDQ and GIS, were devel-
oped from focus groups of GERD patients, and only
the items rated as being of the highest importance
are used in the ﬁnal instruments. Consequently,
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naires encompass the most relevant points that they
are likely to ask in terms of GERD symptoms and
how they affect patients’ everyday lives.
Assessing the impact of GERD
symptoms on HRQL
With the availability of validated questionnaires, the
negative effect of GERD on HRQL is becoming bet-
ter deﬁned. Findings show that subjects with
untreated GERD have lower HRQL than the general
population (13,23–28). In the German ProGERD
(Progression of Gastro-oesophageal Reﬂux Disease)
study, for example, patients with symptoms of GERD
had substantially impaired HRQL in terms of both
physical and psychosocial aspects of well-being com-
pared with the general German population. From a
disease-speciﬁc point of view, patients felt restricted
as a result of food and drink problems, disturbed
sleep, and impaired vitality and emotional well-being
(23). Similar ﬁndings were observed in other large-
scale population surveys (13,24–28). A survey con-
ducted by the National Heartburn Alliance in the
USA, for example, found more than 70% of the
respondents reported reduced enjoyment of food and
that eating out was a problem because of their GERD
symptoms (27). In addition, the majority reported
that heartburn affected their sleep and caused prob-
lems with concentration at work, with over 30% stat-
ing that social activities were curbed by heartburn
(27). Another large US general population survey
found that respondents with nocturnal GERD symp-
toms reported signiﬁcantly greater impairment of
well-being than did respondents who reported having
only daytime GERD symptoms (29).
Notably, impairment of HRQL strongly correlates
with patient-perceived severity and frequency of
GERD symptoms. In a random sample of the general
Swedish population, for example, a decrease in well-
being (as assessed using the Psychological General
Well-Being Index) was signiﬁcantly associated with
Table 1 Patient-reported outcome instruments that have been used to assess the severity of gastro-oesophageal reﬂux disease (GERD) symptoms
and the impact of symptoms on health-related quality of life
Instrument Items and domains Scoring system Scoring interpretation
Generic
SF-36 (15) 36 items grouped into eight domains
(physical function, bodily pain, role
limitations – physical, vitality, general
health perceptions, social function, role
limitations-emotional, mental health)
Scored from 0 (lowest well-being) to 100
(highest well-being); two summary component
scales (physical and mental)
Low score represents worst health state
PGWBI (16) 22 items grouped into six domains (anxiety,
depressed mood, well-being, self control,
general health, vitality)
Items scored on a 6-grade Likert-type scale
(1, worst health to 6, best health). Overall
worst possible score ¼ 22; overall best
possible score ¼ 132
Low score represents worst health state
EQ-5D (17) Five items concerning mobility, self-care,
usual activities, pain/discomfort and
anxiety/depression
Items scored on a 3-grade scale of worsening
health (e.g. Mobility item: ‘no problems
in walking about’ to ‘conﬁned to bed’)
Higher grades represent poorer state
of health
Disease-speciﬁc
QOLRAD (18) 25 items, ﬁve domains (emotional distress,
sleep disturbance, food/drink problems,
vitality, physical/social functioning)
Items scored on a 7-grade Likert-type scale
with regard to degree of distress (7, no to 1,
a great deal of distress) and frequency of the
problem (7, none of the time to 1, all of the
time)
Low score represents more severe impact
on daily functioning
GSRS (19) 15 items, ﬁve symptom clusters (reﬂux,
diarrhoea, constipation, pain, indigestion)
Items scored on a 7-grade Likert-type scale
(1, none at all to 7, very severe discomfort)
High score represents worse discomfort
RDQ (20) 12 items measuring the frequency and
severity of heartburn, regurgitation and
dyspeptic symptoms
Items scored on a 6-grade Likert-type scale
(did not have to daily for frequency; did not
have to severe for severity)
High score represents more frequent and
severe symptoms
GERD Impact
Scale (21)
Nine items measuring three distinct factors
(burning and pain, other acid-related
symptoms, impact of GERD symptoms)
Items scores on a 4-grade scale (never to daily) Higher grades represent worse discomfort
EQ-5D, EuroQoL 5-dimensional health-related quality-of-life questionnaire; GSRS, Gastrointestinal Symptom Rating Scale; RDQ, Reﬂux Disease Questionnaire;
SF-36, Short Form-36; PGWBI, Psychological General Well-Being Index; QOLRAD, Quality of Life in Reﬂux and Dyspepsia.
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tation (p < 0.05) and abdominal pain (p < 0.0001)
based on the GSRS (30). Indeed, even symptoms that
were rated as mild [i.e. GSRS score of £ 3 (the worse
possible score being 7 on this scale)] had a clinically
meaningful adverse effect on well-being. The Swedish
study did not investigate the effect of symptom fre-
quency on well-being. However, data reported else-
where indicate that ‡ 2 days of mild symptoms per
week are sufﬁcient to impair HRQL in patients with
GERD (8,31). These ﬁndings underscore the impor-
tance of incorporating an assessment of HRQL as
part of the management of GERD in primary care,
especially for newly diagnosed patients.
Effective treatment improves HRQL
in patients with GERD
Effective medical management of GERD hinges on the
physician being able to ensure that appropriately
targeted treatment provides enduring relief from
symptoms (and/or prevention of complications) and,
in turn, improvement of HRQL. This objective can
usually be accomplished by sufﬁcient control of gastric
acid secretion (32), and numerous studies show that
successful treatment of symptoms with acid-suppres-
sive therapy leads to marked improvement of HRQL
(33–41). In this regard, the proton pump inhibitors
(PPIs) are the most effective, ﬁrst-line, initial and
long-term therapy for the treatment of patients with
GERD (6–9). The ﬁndings of the ProGERD study
(23), for example, attest to the efﬁcacy of PPI therapy
for improving HRQL in patients with symptoms of
GERD (Figure 2). After treatment, physical and mental
aspects of well-being reached levels similar to those of
the general German population, and the degree of
symptom relief was one of the main factors associated
with improvements in HRQL measures.
Once a patient with GERD is symptom-free,
guidelines advocate that treatment can be stepped
down either to the lowest effective PPI dose that
controls symptoms or to less intensive acid suppres-
sion with a H2-receptor antagonist (6,7). HRQL was
monitored as part of a study that investigated the
use of the step-down approach in the long-term
management of patients with symptoms of GERD
(41). In this study, patients who were relieved of
symptoms (£ 1 day of mild GERD symptoms during
the previous 7 days) after 4 weeks’ initial treatment
with esomeprazole 40 mg/day were randomised to
receive 6 months’ maintenance treatment with
esomeprazole 20 mg/day, esomeprazole 20 mg
on-demand or ranitidine 150 mg twice daily. HRQL,
as assessed using the QOLRAD questionnaire, was
impaired at baseline and improved signiﬁcantly after
initial treatment with esomeprazole. Thereafter, while
ranitidine maintenance therapy was effective for
maintaining HRQL in some patients, both esomep-
razole maintenance regimens proved signiﬁcantly
more effective than continuous treatment with a
In the past week...
Please complete the following questions by marking one response per question.
Consider your symptoms over the past week.
There are no right or wrong answers.
Please be sure to answer every question.
a. Pain in your chest or behind the breast bone?
b. Burning sensation in your chest or behind the breast
bone?
c. Regurgitations or acid taste in your mouth?
d. Pain or burning in your upper stomach?
e. A sore throat or hoarseness that is related to your
heartburn or acid reflux?
3. How often have your symptoms prevented you from
eating of drinking any of the foods you like?
4. How frequently have your symptoms kept you from
being fully productive in your job or daily activities?
5. How often did you take additional medication other
than what the physician told you to take (such as Tums,
Rolaids, Maalox)?
The text of the GERD impact scale is copyright AstraZeneca LP (©2001). All rights reserved.
2. How often have you had difficulty getting a good
night’s sleep because of your symptoms?
1. How often have you had the following symptoms:
Daily Often Sometimes Never
Figure 1 The GERD Impact Scale (available at: http://www.nexium.net/hcp/ScientiﬁcResources/The-GERD-Impact-
Scale.aspx?mid¼35)
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ment in HRQL seen during the symptom control
phase (p < 0.0001 for all QOLRAD dimensions).
Overall, daily esomeprazole therapy was more effec-
tive than esomeprazole on-demand in terms of
enduring symptom relief (41). Ponce et al. (42) also
noted the ability of on-demand therapy with a PPI
to maintain HRQL improved with short-term heal-
ing therapy, but the ﬁndings of the latter study are
somewhat limited by the absence of a comparative
treatment arm of daily maintenance therapy.
Taken together, these ﬁndings outline how PRO
instruments can be easily used by PCPs to monitor
the response of GERD patients to appropriately tar-
geted therapy.
Improving patient-physician
communication and addressing
unmet patient needs
As noted above, it has become standard practice for
PCPs to manage GERD empirically on the basis of
symptom severity and frequency alone (6–9). Tradi-
tionally, symptom evaluation involves the physician
asking appropriate questions to elicit information
from the patient; the physician then interprets the
response and makes a judgment as to the severity of
symptoms. However, there is often poor agreement
between patients and physicians in their assessment
of GERD symptom severity, with physicians tending
to underestimate symptom severity and overestimate
treatment effects (43,44). In turn, physicians are
likely to be failing to recognise the true HRQL
impact of the patient’s GERD symptoms. A separate
study, for example, found that baseline QOLRAD
scores were not strongly correlated with the physi-
cian assessment of overall disease severity (43). This
failure to sufﬁciently account for symptom-related
disability and the effect on HRQL, coupled with
communication difﬁculties between physicians and
patients (45), may therefore result in suboptimal dis-
ease management and contribute to treatment dissat-
isfaction. In the Patient Unmet Needs Survey
(PUNS) of 11,064 chronic heartburn sufferers, for
example, only 46.2% of respondents were totally sat-
isﬁed with their current heartburn medication (46).
Interestingly, respondents who reported complete
heartburn resolution reported higher levels of total
satisfaction (46). Other authors have found that the
greater the improvement on the vitality domain of
QOLRAD questionnaire during PPI therapy the
more likely the patient was to be satisﬁed with the
treatment (47), while those patients who stay on PPI
therapy longer (presumably because of better symp-
tom control) show higher levels of satisfaction with
treatment (as determined by the GERD Treatment
Satisfaction Questionnaire) (48). Therefore, the likes
of the PUNS data and other ﬁndings linking HRQL
outcomes and treatment satisfaction reinforce the
need for more comprehensive assessments of symp-
toms severity and the effect on well-being, using
PRO instruments, both at diagnosis and during
pharmacotherapy to provide more GERD sufferers
with enduring symptom relief.
Although a complete symptomatic response is
quite feasible for most patients in the era of PPI
therapy, it is not uncommon for PPI-treated GERD
patients to have some residual symptoms. The extent
to which patients experience persistent GERD symp-
toms during PPI therapy is not generally appreciated
7
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0
Physical/social sleep dysfunction
functioning
§ Pre: pre-treatment value at baseline
Post:value after 2-week treatment
Emotions Vitality Eating/Drinking
Problems
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Barrett’s esophagus
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Post§
Figure 2 Quality of Life in Reﬂux and Dyspepsia (QOLRAD) questionnaire dimensions, assessed prior to treatment and after
2 weeks of treatment with esomeprazole, in German patients with symptoms suggestive of gastro-oesophageal reﬂux disease;
p < 0.0001 for all changes vs. pretreatment (baseline) (23). Reprinted from Kulig M, et al. Quality of life in relation to
symptoms in patients with gastro-oesophageal reﬂux disease – an analysis based on the ProGERD initiative. Aliment
Pharmacol Ther 2003; 18: 767–76, with permission from Blackwell Publishing. RE, reﬂux oesophagitis (patients received
esomeprazole 40 mg/day for 4 weeks in total); NERD, non-erosive reﬂux disease (patients received esomeprazole 20 mg/day
for 2 weeks)
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the success of this class of medications (43). The
PASS (Proton pump inhibitor Acid Suppression) test
is an example of a simple and clinically applicable
tool that can help PCPs to identify undertreated
patients and assess their response to a change in
therapy. The PASS test is composed of ﬁve, clear,
easy-to-understand (yes/no) questions relevant to
patient experience (49). The utility of the PASS test
was evaluated in patients with persistent GERD
symptoms of at least mild severity despite PPI ther-
apy, who went on to receive open-label treatment
with esomeprazole 40 mg/day for 4 weeks (n ¼ 249).
Mean total PASS test scores, which were > 3 at the
baseline evaluation (against a maximum possible
score of 5), fell to £ 2.0 after 4 weeks’ esomeprazole
therapy, and 30–33% of patients were PASS test
responders (i.e. score of zero after esomeprazole
treatment). PASS test responder effect sizes on the
GSRS, RDQ and QOLRAD were, on average, two to
three times higher than the effect sizes for PASS test
non-responders. In other words, there is a high like-
lihood that if the patient has a PASS test score of
zero (in this case, by switching to a different PPI
with greater acid-suppressive efﬁcacy) then their
HRQL will have also been improved. The GIS has
also proved of value in the identiﬁcation of GERD
patients with uncontrolled symptoms in need of
more effective therapy (21). During validation of the
questionnaire, for example, physicians reported alter-
ing their treatment decision in around one-third of
patients (35%) based on information provided by
the GIS (21).
Physicians should also consider that issues related
to dosing and treatment adherence (compliance)
may be involved when an incomplete response to
PPI therapy is apparent and well-being continues to
be impaired. Once the physician has conﬁrmed that
GERD symptoms are still present during PPI ther-
apy, the challenge will be to determine whether treat-
ment is being taken as prescribed. For example, the
importance of treatment adherence and ingestion of
PPI therapy before a meal should be stressed. If it
can be conﬁrmed that adherence is acceptable and
that residual symptoms are in fact acid-related, e.g.
with 24-h pH monitoring on medication to deter-
mine the presence of reﬂux (7), then the patient may
beneﬁt from an increase in acid-suppressive therapy.
This may be sufﬁcient to bring symptoms under
control and, in turn, improve HRQL.
Conclusions
As the role for PCPs in the management of GERD
continues to evolve and expand, there is increasing
potential for them to improve the value of their care
services for GERD patients. A better understanding
of each patient’s personal experience of the disease,
which can be easily captured with the use of PRO
instruments, will help PCPs to appreciate that even
mild symptoms of GERD can be troublesome and
can be associated with a clinically relevant reduction
in patient well-being. Indeed, HRQL is now a com-
ponent of the deﬁnition of GERD and its improve-
ment is considered to reﬂect successful therapeutic
intervention. Consequently, a need exists for
improved questioning during consultation and more
effective and open communication to assist in elicit-
ing the most relevant information from patients.
This process can be augmented by the use of relevant
PRO instruments such as the GIS, which is practical
and easy to incorporate into everyday primary care
practice. Primary care physicians are therefore
encouraged to increase their knowledge of PRO
instruments and make wider use of these valuable
tools as part of their management of patients with
GERD, given that such questionnaires can facilitate
patient communication and help physicians under-
stand and satisfy the needs of patients with GERD.
In doing so, clinical outcomes may be improved and
patient satisfaction increased, with strengthening of
the relationships between patients and their physi-
cians.
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